Michael Baker's presentation at the November 2021 Online Investor Event (money management News Network)
Learn more about Arovella Therapeutics and our Licence Agreement with Imperial College London, providing us with the exclusive, global rights to commercialise its invariant Natural Killer T (iNKT) Cell Therapy Platform for the treatment of human disease. #CellTherapy #ASX #NaturalKiller #HumanDisease #CancerTreatment Disclaimer: If you own the YouTube channel related to this video and do … Read more